54166-96-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-6-methoxy-benzoic acid methyl ester is used as an intermediate in the synthesis of various pharmaceutical compounds for its potential biological and pharmacological activities. Its unique structure allows it to be a versatile building block in the development of new drugs with therapeutic applications.
Used in Organic Synthesis:
2-Amino-6-methoxy-benzoic acid methyl ester is used as a key component in organic synthesis for the preparation of a wide range of organic compounds. Its presence of an amino and methoxy group provides opportunities for further chemical reactions, making it a useful precursor in the synthesis of various organic molecules with diverse applications.

Upstream product

• 77901-52-1 methyl 2-methoxy-6-nitrobenzoate 
• 603-12-3 2,6-dinitrobenzoic acid 
• 67765-42-8 5-methoxy-2,4-dihydro-1H-3,1-benzoxazine-2,4-dione 
• 606-45-1 2-methoxybenzoic acid methyl ester 
• 4837-88-1 6-methoxy-2-nitrotoluene 
• 5460-31-1 3-nitro-o-cresol 
• 53967-73-0 2-nitro-6-methoxybenzoic acid 
• 53600-33-2 6-methoxyanthranilic acid 
• 67-56-1 methanol 
• 1146214-77-8 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid methyl ester 
• 186581-53-3 diazomethane 
• 42087-82-1 methyl 2,6-dinitrobenzoate 
• 606-20-2 2,6-dinitrotoluene 

Downstream Products

• 54166-69-7 2'-carboxy-3'-methoxyoxanilic acid 1-ethyl 2'-methyl ester 
• 94654-53-2 N-(3-methoxy-2-methoxycarbonylphenylamino)benzoic acid 
• 936479-46-8 methyl 6-chloro-2-methoxybenzoate 
• 697801-52-8 5-methoxy-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one 
• 697801-53-9 5-hydroxy-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one 
• 1380698-91-8 2-[2-amino-6-(methyloxy)phenyl]-2-propanol 
• 18362-30-6 2-chloro-6-hydroxybenzaldehyde 
• 29866-54-4 2-chloro-6-methoxybenzaldehyde 
• 1154740-80-3 6-chloro-2H-chromene-3(4H)-one 
• 1038726-89-4 2-chloro-6-methoxyphenylmethanol 

Relevant academic research and scientific papers

Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors

With a resurgence in interest in covalent drugs, there is a need to identify new moieties capable of cysteine bond formation that are differentiated from commonly employed systems such as acrylamide. Herein, we report on the discovery of new alkynyl benzoxazine and dihydroquinazoline moieties capable of covalent reaction with cysteine. Their utility as alternative electrophilic warheads for chemical biological probes and drug molecules is demonstrated through site-selective protein modification and incorporation into kinase drug scaffolds. A potent covalent inhibitor of JAK3 kinase was identified with superior selectivity across the kinome and improvements in in vitro pharmacokinetic profile relative to the related acrylamide-based inhibitor. In addition, the use of a novel heterocycle as a cysteine reactive warhead is employed to target Cys788 in c-KIT, where acrylamide has previously failed to form covalent interactions. These new reactive and selective heterocyclic warheads supplement the current repertoire for cysteine covalent modification while avoiding some of the limitations generally associated with established moieties.

Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Since the discovery of HIV as the etiological agent of AIDS, the virus has infected millions of people each year. Fortunately, with the use of HAART, viremia can be suppressed to below detectable levels in the infected individuals, which significantly improves their quality of life and prevents the onset of AIDS. However, HAART is not curative and issues relating to adherence and drug resistance may lead to the re-emergence of viremia, the development of AIDS, and ultimately death. To address a pressing need for the development of new and efficacious antiretroviral agents with activity against viruses bearing prevalent resistant mutations, we have designed two generations of benzimidazolone derivatives as HIV non-nucleoside reverse transcriptase inhibitors. The first generation benzimidazolone inhibitors were found to be potent inhibitors of wild-type HIV reverse transcriptase but were ineffective in the presence of common resistance mutations such as K103N and Y181C. A second generation benzimidazolone inhibitor (compound 42) not only showed inhibitory activity against wild-type HIV but also remained active against HIV containing the K103N, Y181C, and K103N/Y181C drug resistance mutations.

Derivative of azaphenalene-3-ketone and preparation method and application thereof

The invention relates to a derivative of azaphenalene-3-ketone and a preparation method and an application thereof and belongs to the technical field of medicine synthesis. The structure of the derivative is as follows: a formula as shown in the descripti

N,B-bidentate boryl ligand-supported iridium catalyst for efficient functional-group-directed C-H borylation

Convenient silylborane precursors for introducing N,B-bidentate boryl ligands onto transition metals were designed, prepared, and employed in ready formation of irdium(IIl) complexes via Si-B oxidative addition. A practical, efficient catalytic ortho-borylation reaction of arenes with a broad range of directing groups was developed using an in situ generated catalyst from the silylborane preligand 3c and [IrCl(COD)]2.

QUINAZOLINE-BASED KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Discovery of novel bacterial RNA polymerase inhibitors: Pharmacophore-based virtual screening and hit optimization

The bacterial RNA polymerase (RNAP) is a validated target for broad spectrum antibiotics. However, the efficiency of drugs is reduced by resistance. To discover novel RNAP inhibitors, a pharmacophore based on the alignment of described inhibitors was used for virtual screening. In an optimization process of hit compounds, novel derivatives with improved in vitro potency were discovered. Investigations concerning the molecular mechanism of RNAP inhibition reveal that they prevent the protein-protein interaction (PPI) between σ70 and the RNAP core enzyme. Besides of reducing RNA formation, the inhibitors were shown to interfere with bacterial lipid biosynthesis. The compounds were active against Gram-positive pathogens and revealed significantly lower resistance frequencies compared to clinically used rifampicin.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein c, X, Y, R2, R4 and R5 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The present invention relates to compounds of formula (I) wherein c, X, Y, R2, R3, R4 and R6 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.